nervennahrung fürs depot - 500 Beiträge pro Seite

[bleicher]

die großen zivilisationskrankheiten wie alzheimer, depressionen und multipler sklerose haben eines gemeinsam: ihre wurzeln liegen im nervensystem verborgen. neurocrine hat ihnen den kampf angesagt.
die neurologie, die lehre vom aufbau und von der funktion des nervensystems, ist der versuch des menschen, das wahrscheinlich bestgehütetste geheimnis seines körpers wissenschaftlich zu erfassen. selbst die moderne medizin, mit all ihrer technik kratzt derzeit wohl nur an der oberfläche, versucht das hochkomplexe molekulare zusammenspiel zwischen neuralem, peripherem und vegetativem nervensystem und deren interaktionen mit dem körpereigenen immun- und endokrinsystem zu verstehen.
doch eines scheint heute sicher: das nervensystem spielt eine zentrale rolle bei der entstehung vieler krankheiten. schädigungen der nerven gehen mit körperlichen folgeerscheinungen einher. nur unternehmen, die auf diesem gebietder forschung in den nächsten jahren wichtige fortschritte erzielen, werden in der lage sein, hochwirksame medikamente herzustellen. zu den pionieren unter den "nervenforschern" zählt ganz sicher die us-gesellschaft neurocrine biosciences.

http://www.neurocrine.com/images/clinic_2.gif

am weitesten fortgeschritten ist der wirkstoff nbi-34060. dabei handelt es sich um ein präparat gegen schlaflosigkeit, das sich gegenwärtig in phase II der klinischen studien befindet. dessen marktpotenzial läßt sich auf mindestens 1 milliarde us$ veranschlagen.
zur nachhaltigen finanzierung der forschungsprogramme arbeitet man unter anderem mit dem pharmakonzern eli lilly zusammen.

http://www.neurocrine.com/images/res_pipe_32701.jpg

die entwicklung der umsatzzahlen der vergangenen jahre verspricht in naher zukunft einen bevorstehenden sprunghaften anstieg. ich schätze, das die einführung eines ersten medikamentes in 2003 ansteht, was dem aktienkurs schon im nächsten jahr zugute kommen könnte...denn die börse ist vorausschauend.

http://199.230.26.96/cgi-bin/ir/nbix/keystat.html

weiterhin rechne ich mit einer nachhaltigen erholung der wirtschaft im nächsten jahr, so das zunehmend mehr geld an die börse fließen wird.
noch ist der titel nicht im fokus der anleger. bei kursrückschlägen sollte man erste positionen aufbauen. schaut man sich den chart an wird deutlich, das die aktie in letzter zeit relative stärke bewiesen hat. momentan bewegt sie sich in richtung eines neuen allzeithochs.

http://chart.bigcharts.com/bc3/quickchart/chart.asp?symb=nbi…


schaut euch mal um (z.b. www.neurocrine.com) und macht euch ein eigenes bild.
ich werde meine stücke jedenfalls im depot belassen, weil ich der meinung bin eine gute aktie gekauft zu haben, welche potenzial besitzt mir noch eine menge freude zu bereiten.
aber vorsicht, biotech-aktien unterliegen mitunter hohen schwankungen...sie sind riskant...versprechen aber auch eine überdurchschnittliche performance.

[bleicher]

sorry, aber die bilder kamen nicht an wie sie sollten:

[bleicher]

Article for Neurocrine Biosciences Inc (NASDAQ NM:NBIX) 7:00 AM

most recent headlines





Neurocrine Biosciences Initiates Phase III Clinical Trial For NBI-34060 in Chronic (Primary) Insomnia
FRIDAY, NOVEMBER 16, 2001 7:00 AM
- PRNewswire

Neurocrine Biosciences Initiates Phase III Clinical Trial For NBI-34060 in Chronic (Primary) Insomnia

11/16/2001 7:00:00 AM
SAN DIEGO, Nov 16, 2001 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that it has initiated the first pivotal Phase III clinical trial of NBI-34060 in approximately 500 patients with chronic (primary) insomnia. The Phase III clinical trial is a randomized, double blind, parallel-group, multi-center study to evaluate the safety of two doses of NBI-34060 Immediate Release (IR) for the long-term treatment of chronic (primary) insomnia in adults. The trial will be conducted in approximately 40 medical sites in the United States and Europe.

"This trial is a major turning point for Neurocrine as we begin our first Phase III program in the history of the Company," said Gary A. Lyons, President and CEO of Neurocrine Biosciences.

"Two additional pivotal Phase III trials with NBI-34060-IR are planned to initiate shortly. We are implementing an aggressive Phase III clinical evaluation of NBI-34060 to support registration of this new sedative hypnotic for short-term and long-term treatment of insomnia," said Henry Pan, M.D. Ph.D, Executive Vice President of Clinical Development and Chief Medical Officer for Neurocrine Biosciences.

Background on NBI-34060 for Insomnia

NBI-34060 is a non-benzodiazepine that acts on a specific site of the GABA-A receptor. It is through this same mechanism that the non-benzodiazepine therapeutics currently on the market produce their sleep-promoting effects.

Insomnia is a prevalent neurological disorder in the United States, with about one-half of the adult population reporting trouble sleeping a few nights per week or more, according to the National Sleep Foundation (NSF). Approximately 29% of the adult population reports that they experience insomnia every night or almost every night. Despite this widespread prevalence, insomnia remains a disorder with high unmet medical needs, including the ability to maintain sleep throughout the night without next-day residual effects.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders. Neurocrine Biosciences, Inc. news releases are available through the Company`s website via the Internet at http://www.neurocrine.com .

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward looking statements are risks and uncertainties associated with Neurocrine`s development programs and business and finances including, but not limited to, risk that Neurocrine`s development programs will not successfully proceed through all phases of clinical trials or that in later stage clinical trials will not show that Neurocrine`s product candidates are effective in treating humans; determinations by regulatory and governmental authorities; uncertainties relating to patent protection and intellectual property rights of third parties; impact of competitive products and technological changes; availability of capital and cost of capital; and other material risks. A more complete description of these risks can be found in the Company`s Annual Form 10K for the year ended December 31, 2000, as amended, the quarterly report on form 10Q for the quarter ended September 30, each of which should be read before making any investment in Neurocrine common stock. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

[bleicher]

na bitte, es geht doch!
neues allzeithoch markiert...
nachdem am 16.11.01 der eintritt in die dritte und entscheidende testphase des medikamentes nbi-34060 (gegen schlaflosigkeit) eingeläutet wurde, konnte trotz eines unentschiedenen gesamtmarktes der wert neue höchststände erklimmen.

[puhvogel]

@bleicher: Sehr schön, das Du mal einen eher unbekannteren Wert hier en detail und bebildert vorstellst!
Drei Anmerkungen zu Neurocrine:

1) Der Wert erscheint optisch recht teuer für bisher nur Phase 2 Medikamente

2) Allerdings ist das Management ein wahrer Meister im Ausspielen von Pharmafirmen. Auf der Wegstrecke blieb Janssen & Janssen, der neue Partner heisst Glaxo. Das Management ist top!

3) Die Hauptindikation für CRF-Rezeptoren sind Angsterkrankungen. Das ist ein echter Blockbustermarkt, bei denen sie mit Firmen wie IPIC/Pfizer konkurrieren.
Bei destruktive Erkrankungen wie Alzheimer oder Schlaganfall sehe ich dagegen keine direkte Anwendung.

Solange das Ding läuft, gibt es keinen Grund zu verkaufen.

[g.o.d.]

Neurocrine, Pfizer Announce Worldwide Agreement To Develop, Promote Insomnia Treatment
THURSDAY, DECEMBER 19, 2002 10:30 AM
- PR Newswire

SAN DIEGO, and NEW YORK, Dec 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc. (NBIX) and Pfizer Inc today announced a global agreement for the exclusive worldwide development and commercialization of indiplon, Neurocrine`s Phase III compound for the treatment of insomnia. In addition, Neurocrine will have the opportunity to detail Pfizer`s antidepressant Zoloft(R) (sertraline HCl).

Under terms of the collaboration, which is subject to government approval, Neurocrine will receive an initial payment of $100 million and up to $300 million in milestone payments. Pfizer will fund the ongoing development of indiplon and pay royalties on worldwide sales and co-promotion fees in the United States. The companies will collaborate on the clinical development of indiplon and co-promote the product in the United States; Pfizer will hold an exclusive license to develop and market indiplon outside the United States.

Pfizer also will support the creation of a 200-member Neurocrine sales force to reach psychiatrists and sleep specialists. This sales force will detail Zoloft to U.S. psychiatrists after Neurocrine submits the indiplon New Drug Application to the U.S. Food and Drug Administration, which could be as early as year-end 2003. Following the U.S. launch of indiplon, Pfizer will grant Neurocrine a staged $175 million secured short-term credit facility.

"We are excited to have the world`s leading pharmaceutical company as our partner in developing and bringing this important new treatment option to patients," said Gary Lyons, president and chief executive of San Diego-based Neurocrine. "Indiplon has the potential to become the first sleep medication indicated for multiple features of insomnia.

"Further, detailing Zoloft in the United States will allow Neurocrine`s new sales force to establish relationships with psychiatrists before the launch of indiplon," he said. "As many patients with sleep disorders also suffer from psychiatric conditions, psychiatrists are key providers of care to these patients."

While the prevalence of insomnia is unknown, surveys suggest that up to 50 percent of adults have difficulty sleeping from time to time. The vast majority of people who regularly suffer from the inability to initiate and maintain sleep are untreated and undiagnosed. Insomnia often has a serious impact on a patient`s general health and quality of life, including impaired daytime functioning and decreased work productivity.

Indiplon, which Neurocrine licensed from DOV Pharmaceuticals, is a non-benzodiazepine that acts on a specific site of the GABA-A receptor. Indiplon is being studied in both immediate release and modified release formulations to address the problems of sleep initiation and maintenance as well as middle of the night awakenings.

Data have shown that indiplon is both efficacious and well tolerated in achieving rapid sleep induction without next-day residual effects.

"Getting patients to sleep through the night and awake rested and refreshed is the key objective of treatment," said Hank McKinnell, Pfizer chairman and chief executive officer. "We are very pleased to be able to work with Neurocrine on this innovative treatment option. Indiplon has been shown to address the unmet needs of patients who can`t fall asleep as well as those who wake in the night."

Neurocrine Biosciences Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The company`s product candidates address some of the largest pharmaceutical markets in the world, including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders.

Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world`s best-known consumer brands.

DISCLOSURE NOTICE: The information contained in this document is as of December 19, 2002. Pfizer assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments.

This document contains forward-looking information about a product in development that involves inherent uncertainties. The success of this research and development project and the speed with which regulatory authorizations and the launch of the product may be achieved, as well as competitive factors, could affect the actual outcome of this collaboration.

A further list and description of the risks, uncertainties and other matters that could cause the Pfizer`s description contained herein to differ materially can be found in the Company`s Annual Report on Form 10-K for the fiscal year ended December 31, 2001, and in its periodic reports on Forms 10-Q and 8-K (if any).


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X88945274


SOURCE Pfizer Inc; Neurocrine Biosciences, Inc.

Mariann Caprino of Pfizer, [phone]; Elizabeth Foster or
Paul Hawran of Neurocrine, [phone]
/Company News On-Call: Pfizer`s press releases are available through PR
Newswire`s Company News On-Call service on PRN`s Web Site. Visit
http://www.prnewswire.com/comp/688250.html
/Photo: A free corporate logo to accompany this story is available
immediately via Wieck Photo Database to any media with telephoto receiver or
electronic darkroom, PC or Macintosh, that can accept overhead transmissions.
To retrieve a logo, please call 972-392-0888.
/Company News On-Call: http://www.prnewswire.com/comp/688250.html


http://www.pfizer.com


Copyright (C) 2002 PR Newswire. All rights reserved.